A 32-year-old male from Delhi presents to the de-addiction centre with a 6-year history of heroin use. He reports using 2–3 grams daily via inhalation ("chasing the dragon"). He has attempted self-withdrawal three times but relapsed within 2 weeks each time due to severe anxiety, insomnia, and body aches. On examination, he is alert, with dilated pupils and mild tremor. His vital signs are stable. He is keen on medication-assisted treatment. Which of the following is the most appropriate pharmacological approach for long-term management of his opioid use disorder?

Explanation

## Pharmacological Management of Opioid Use Disorder **Key Point:** Buprenorphine monotherapy (or buprenorphine-naloxone) is the preferred first-line medication-assisted treatment (MAT) for opioid use disorder in India, owing to its superior safety profile, office-based prescribing feasibility, and regulatory availability under the NDPS Act amendments. ### Clinical Note on Pupil Finding The stem mentions **dilated pupils**, which is atypical for a patient actively using heroin — opioids cause **miosis (constriction)**. Dilated pupils would be expected during **opioid withdrawal** or with co-ingestion of a stimulant. This clinical inconsistency does not alter the management decision: the 6-year history of heroin use with three failed self-withdrawal attempts clearly mandates long-term MAT. ### Why Buprenorphine Is Optimal Here Buprenorphine (0.4–32 mg/day sublingual) is the gold standard for opioid use disorder in outpatient and resource-limited settings in India because: 1. **Partial agonist action** — lower abuse potential and overdose risk compared to methadone (full agonist) 2. **Ceiling effect on respiratory depression** — fatal overdose risk is substantially lower than with methadone 3. **Longer half-life** (24–72 hours) — allows once-daily dosing, improving adherence 4. **Office-based prescribing** — licensed physicians can prescribe buprenorphine under India's NDPS Act (amended 2014); methadone is restricted to government-approved Opioid Substitution Therapy (OST) centres only (e.g., AIIMS, NIMHANS) 5. **Legal and regulatory context** — NACO and UNODC guidelines for India explicitly recommend buprenorphine as the practical first-line MAT agent in outpatient settings; methadone, while equally efficacious globally, requires daily supervised dispensing at designated government centres, making it logistically restrictive for most patients ### Comparison of Maintenance Agents | Feature | Methadone | Buprenorphine | Naltrexone | Clonidine | |---------|-----------|---------------|------------|-----------| | Receptor action | Full agonist | Partial agonist | Full antagonist | α2-agonist | | Overdose risk | High | Low (ceiling effect) | None | Low | | Withdrawal on cessation | Severe, prolonged | Mild–moderate | Precipitated (severe) | N/A | | Abuse potential | High | Low | None | Low | | Setting in India | Govt. OST centres only | Office-based | Office-based | Detox only | | Role | Maintenance | Maintenance | Relapse prevention | Symptomatic detox | ### Why the Other Options Are Less Appropriate - **Methadone (D):** Highly effective globally and preferred for high-dose, long-duration opioid dependence in many Western guidelines. However, in **India**, methadone is available only at government-designated OST centres and requires daily supervised dosing — making it logistically impractical as a first-line choice for most outpatients. Per NACO/UNODC India guidelines, buprenorphine is the preferred first-line agent. - **Naltrexone (C):** Requires a 7–10 day opioid-free period before initiation; premature use precipitates severe withdrawal. Compliance is poor without supervised administration (e.g., depot formulation). Not suitable as first-line for a patient with high relapse risk and no opioid-free interval established. - **Clonidine (B):** An α2-adrenergic agonist that attenuates autonomic withdrawal symptoms (sweating, tachycardia, hypertension) but does **not** reduce craving or prevent relapse. It is used only as an adjunct during short-term detoxification, not for long-term maintenance. **High-Yield:** Per NACO's Opioid Substitution Therapy guidelines and WHO recommendations, buprenorphine is the preferred MAT agent in India for outpatient management of opioid use disorder. Methadone, while equally efficacious, is restricted to specialised government centres in India (KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; NACO OST Guidelines 2014). ### Clinical Pearl This patient's three failed self-withdrawal attempts with relapse within 2 weeks each time indicates **high neurobiological relapse risk** — he requires long-term MAT, not detoxification alone. Psychosocial support (cognitive–behavioural therapy, contingency management, family involvement) must accompany pharmacotherapy; buprenorphine monotherapy without counselling carries a 50–60% relapse rate, whereas combined treatment achieves >70% retention at 12 months (Mattick et al., Cochrane Review 2014). **Mnemonic: BUPE-SAFE** — Buprenorphine: Partial agonist, Safer in overdose, Flexible dosing, Easy induction, Suitable for office-based care in India.